Compare · MDLN vs QNRX
MDLN vs QNRX
Side-by-side comparison of Medline Inc. (MDLN) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 4601.6x QNRX ($10.2M).
- Over the past year, MDLN is down 12.5% and QNRX is down 25.8% - MDLN leads by 13.2 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 3 for QNRX).
- MDLN has more recent analyst coverage (25 ratings vs 0 for QNRX).
PerformanceMDLN-12.54%QNRX-60.30%
2025-12-17+0.00%2026-08-25
- Company
- Medline Inc.
- Quoin Pharmaceuticals Ltd.
- Price
- $35.64+2.77%
- $5.33-5.16%
- Market cap
- $46.86B
- $10.2M
- 1M return
- -10.28%
- +25.41%
- 1Y return
- -12.54%
- -25.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 0
QNRX
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest QNRX
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events
- Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
- SEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
- SEC Form PRE 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
- Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003